Change in antimicrobial resistance rates in Pseudomonas aeruginosa isolates by years: Analysis for seven years
Küçük Resim Yok
Tarih
2025
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Refik Saydam National Public Health Agency (RSNPHA)
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Objective: Pseudomonas aeruginosa is naturally resistant to many antimicrobial drugs, and resistance rates against currently available antimicrobials may vary according to different geographical regions, hospitals and years. The ability to develop resistance to antimicrobials during the treatment of infections causes treatment difficulties and requires constant monitoring of the resistance profile. This study aimed to retrospectively determine the resistance rates of P. aeruginosa strains isolated from different culture samples sent to the microbiology laboratory from hospitalized patients to various antimicrobials and to examine their changes over the years. Methods: 1746 P. aeruginosa isolates grown in inpatient culture samples sent to the microbiology laboratory from all clinics between January 2016 and December 2022 were evaluated retrospectively. Vitek 2 Compact automated system (BioMérieux, France) was used for antimicrobial susceptibility testing (AST). AST results were evaluated according to Minimum Inhibitory Concentration (MIC) values according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines. EUCAST and Clinical and Laboratory Standards Institute (CLSI) guidelines only approve the broth microdilution method for colistin resistance, so colistin resistance rates were not included in our study. Results: P. aeruginosa strains were isolated most frequently from respiratory tract samples (57.2%) and urine samples (24.5%), and most frequently from samples sent from Intensive Care Units (ICU) (60.4%). The lowest antimicrobial resistance rates for all strains isolated in seven years were amikacin (16.3%) and ceftazidime (22.3%), while meropenem resistance was 33.6% and imipenem resistance was 44.3%. Ciprofloxacin (47.9%) and piperacillin-tazobactam (51.1%) were found to be the antimicrobials with the highest resistance rates. Resistance rates for all other antimicrobials, except amikacin and aztreonam, increased significantly from 2016 to 2022 (p<0,001- p:0,002). Conclusion: In our study, amikacin and ceftazidime were determined to be the most effective antibiotics for P. aeruginosa strains, and there are increasing resistance rates against antimicrobials over the years. Continuous monitoring of antimicrobial resistance rates for each hospital will contribute to the determination of empirical treatment options and appropriate treatment approaches. © 2025 Elsevier B.V., All rights reserved.
Açıklama
Anahtar Kelimeler
Antimicrobial resistance, EUCAST, Pseudomonas aeruginosa
Kaynak
Turk Hijyen ve Deneysel Biyoloji Dergisi
WoS Q Değeri
Scopus Q Değeri
Q4
Cilt
82
Sayı
3
